Grufity logoGrufity logo

Denali Therapeutics Inc Stock Research

DNLI

31.47USD+0.94(+3.08%)Market Closed

Market Summary

USD31.47+0.94
Market Closed
3.08%

DNLI Alerts

DNLI Stock Price

DNLI RSI Chart

DNLI Valuation

Market Cap

3.9B

Price/Earnings (Trailing)

-12.88

Price/Sales (Trailing)

32.03

Price/Free Cashflow

-15.36

DNLI Price/Sales (Trailing)

DNLI Profitability

Return on Equity

-37.29%

Return on Assets

-24.65%

Free Cashflow Yield

-6.51%

DNLI Fundamentals

DNLI Revenue

Revenue (TTM)

112.4M

Revenue Y/Y

128.78%

Revenue Q/Q

24.53%

DNLI Earnings

Earnings (TTM)

-302.6M

Earnings Y/Y

-22.12%

Earnings Q/Q

-75.7%

Price Action

52 Week Range

20.2439.43
(Low)(High)

Last 7 days

8.3%

Last 30 days

18.3%

Last 90 days

6.3%

Trailing 12 Months

0.1%

DNLI Financial Health

Current Ratio

3.16

DNLI Investor Care

Shares Dilution (1Y)

1.69%

Diluted EPS (TTM)

-2.47

Peers (Alternatives to Denali Therapeutics)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
135.3B
26.3B
-2.97% 16.81%
19.8
5.14
2.18% 21.86%
105.0B
27.1B
-0.99% 30.15%
31.49
3.87
-1.26% -54.91%
73.3B
21.4B
7.28% 27.41%
6.23
3.43
80.80% 66.62%
41.9B
10.4B
5.85% 32.49%
14.62
4.04
-6.64% 85.32%
10.4B
1.4B
-8.79% 49.41%
178.74
7.49
29.86% -86.92%
MID-CAP
3.9B
-
18.31% 0.06%
-12.88
32.03
-41.50% -1123.42%
3.2B
-
23.33% -24.11%
-10.12
59.51
215916.67% 21.41%
SMALL-CAP
1.7B
432.8M
17.41% -21.00%
20.97
3.87
1042.97% 128.67%
1.4B
-
35.16% 1.79%
-2.74
20.84
745.14% 12.80%
1.3B
3.1M
-3.43% 39.57%
-8.78
417.83
7.05% -46.74%
886.0M
1.8B
24.61% -84.52%
-0.67
0.48
53.41% -22.97%
574.9M
69.0M
-39.96% -83.45%
-1.96
8.33
26.22% -49.52%
565.8M
112.1M
28.78% -35.14%
-3.18
5.05
3.26% 1.99%
142.4M
-
42.67% -74.19%
-1.36
418.24
-71.03% -64.56%
6.7M
-
67.66% -93.12%
-0.11
3.21
0.51% -141.69%

Financials for Denali Therapeutics

Income Statement (Last 12 Months)
(In Millions)
Description(%) Q/Q2022Q32022Q22022Q12021Q42021Q3
Revenue-100.0%null1128349120
Operating Expenses5.0%423403374344328
  S&GA Expenses4.6%8985837975
  R&D Expenses5.1%334318291265252
Net Income-6.6%-302.57-283.86-285.76-290.5830
Net Income Margin-6.6%-2.69*-2.53*-3.45*-5.97*-
Free Cahsflow-8.5%-253.58-233.80-243.00-219.89-
* denotes actual numbers (not divided by Millions)
Balance Sheet
(In Millions)
Description(%) Q/Q2022Q32022Q22022Q12021Q42021Q3
Assets-5.0%1,2281,2921,3211,4041,450
  Current Assets2.1%1,1391,1159888971,056
    Cash Equivalents-23.5%119155105293396
  Net PPE7.7%4239383940
Liabilities2.0%416408403442438
  Current Liabilities3.6%36134834137854
Shareholder's Equity-8.3%8118849189621,012
  Retained Earnings-13.4%-872.31-769.01-710.22-645.00-569.73
  Additional Paid-In Capital1.8%1,6941,6641,6361,6081,581
Accumulated Depreciation-29----
Shares Outstanding0.5%124123123122122
* denotes actual numbers (not divided by Millions)
Cashflow (Last 12 Months)
(In Millions)
Description(%) Q/Q2022Q32022Q22022Q12021Q42021Q3
Cashflow From Operations-7.0%-237.55-221.93-233.26-211.39368
  Share Based Compensation3.8%9793908577
Cashflow From Investing55.6%-54.58-123.00-114.10-21.63-348.22
Cashflow From Financing12.8%1614171924

Risks for DNLI

What is the probability of a big loss on DNLI?

100%


Probability that Denali Therapeutics stock will be more than 20% underwater in next one year

91.2%


Probability that Denali Therapeutics stock will be more than 30% underwater in next one year.

54.6%


Probability that Denali Therapeutics stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does DNLI drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Denali Therapeutics was unfortunately bought at previous high price.

Drawdowns

Returns for DNLI

Cumulative Returns on DNLI

7.2%


5-Year Cumulative Returns

8.2%


3-Year Cumulative Returns

What are the long-term rolling returns for DNLI?

FIve years rolling returns for Denali Therapeutics.

Annualized Returns

Which funds bought or sold DNLI recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2023-01-26
STRS OHIO
unchanged
-
-97,000
937,000
-%
2023-01-25
Lindbrook Capital, LLC
added
28.16
873
9,873
-%
2023-01-25
Clarius Group, LLC
unchanged
-
-751,000
7,247,000
0.65%
2023-01-24
BAILLIE GIFFORD & CO
added
2.75
-31,133,000
420,472,000
0.44%
2023-01-23
Allspring Global Investments Holdings, LLC
reduced
-2.14
-10,840
90,160
-%
2023-01-18
Activest Wealth Management
unchanged
-
-357
3,643
-%
2023-01-18
EXCHANGE TRADED CONCEPTS, LLC
added
18.75
5,000
72,000
-%
2023-01-17
ARTHUR M. COHEN & ASSOCIATES, LLC
unchanged
-
-44,450
426,550
0.12%
2023-01-17
Ronald Blue Trust, Inc.
added
33.33
-
-
-%
2023-01-13
Allworth Financial LP
unchanged
-
222
222
-%

1–10 of 42

Latest Funds Activity

Are funds buying DNLI calls or puts?
Calls
Puts
Are funds bullish or bearish(Calls - Puts)?
Net Call Options
No. of funds that own DNLI
No. of Funds

Denali Therapeutics News

Best Stocks

Denali Therapeutics Inc. stock held by Barclays PLC is being ....

Best Stocks,
12 hours ago

StreetInsider.com

Silicon Valley Business Journal

Schedule 13G FIlings of Denali Therapeutics

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Jan 20, 2023
baillie gifford & co
11.13%
15,119,474
SC 13G/A
Feb 14, 2022
bratton douglas k
6.4%
7,845,189
SC 13G/A
Feb 14, 2022
price t rowe associates inc /md/
3.7%
4,635,433
SC 13G/A
Feb 09, 2022
vanguard group inc
6.68%
8,161,530
SC 13G/A
Feb 09, 2022
fmr llc
-
0
SC 13G/A
Feb 08, 2022
arch venture fund viii, l.p.
-
0
SC 13G/A
Feb 03, 2022
blackrock inc.
6.6%
8,110,822
SC 13G/A
Jan 18, 2022
baillie gifford & co
12.33%
15,056,381
SC 13G/A
Feb 16, 2021
flagship ventures fund v, l.p.
2.2%
2,730,263
SC 13G/A
Feb 16, 2021
price t rowe associates inc /md/
5.3%
6,464,826
SC 13G

DNLI Fair Value

Recent SEC filings of Denali Therapeutics

View All Filings
Date Filed Form Type Document
Jan 20, 2023
SC 13G/A
Major Ownership Report
Jan 19, 2023
4
Insider Trading
Jan 10, 2023
4
Insider Trading
Jan 09, 2023
4
Insider Trading
Jan 09, 2023
4
Insider Trading
Jan 09, 2023
4
Insider Trading
Jan 09, 2023
4
Insider Trading
Jan 09, 2023
4/A
Insider Trading
Jan 09, 2023
8-K
Current Report
Jan 05, 2023
4
Insider Trading

Latest Insider Trading transactions for DNLI

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2023-01-17
Schuth Alexander O.
acquired
52,800
5.28
10,000
cofo and secretary
2023-01-17
Schuth Alexander O.
sold
-295,339
29.5339
-10,000
cofo and secretary
2023-01-09
Ho Carole
sold
-41,552.3
28.48
-1,459
chief medical officer
2023-01-06
Ho Carole
sold
-41,600.2
28.67
-1,451
chief medical officer
2023-01-05
Schuth Alexander O.
sold
-74,967.8
28.44
-2,636
cofo and secretary
2023-01-05
Krognes Steve E.
sold
-84,466.8
28.44
-2,970
-
2023-01-05
Watts Ryan J.
sold
-136,512
28.44
-4,800
president and ceo
2023-01-05
Ho Carole
sold
-74,967.8
28.44
-2,636
chief medical officer
2023-01-04
Schuth Alexander O.
sold
-83,574.4
28.7
-2,912
cofo and secretary
2023-01-04
Ho Carole
sold
-83,574
28.69
-2,913
chief medical officer

1–10 of 50

Ryan J. Watts
380
Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatment of Parkinson's disease. The company also develops DNL310 that is in Phase I/II clinical trials for the treatment of hunter syndrome; DNL343, which is in phase 1 clinical trial the treatment of amyotrophic lateral sclerosis (ALS); AR443820/DNL788 completed a phase I clinical trial for the treatment of ALS, multiple sclerosis (MS), and Alzheimer's disease; and SAR443122/DNL758, which is in phase II clinical trial for the treatment of cutaneous lupus erythematosus. It has collaboration agreement with Takeda Pharmaceutical Company, Genentech, Inc., Sanofi, F-star Gamma Limited, F-star Biotechnologische Forschungs-Und Entwicklungsges M.B.H, F-star Biotechnology Limited, SIRION Biotech GmbH, Genzyme Corporation, Harvard University, the Michael J. Fox Foundation, and Centogene; and a research and option agreement with Secarna Pharmaceuticals GmbH & Co. KG. to develop antisense therapies in the field of neurodegenerative diseases. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.

DNLI Income Statement

2022-09-30
Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($)
$ in Thousands
3 Months Ended9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Collaboration revenue:    
Collaboration revenue from customers[1]$ 184$ 5,285$ 94,805$ 36,143
Other collaboration revenue3,37503,3754
Total collaboration revenue3,5595,28598,18036,147
Operating expenses:    
Research and development[2]87,78671,559266,621197,477
General and administrative23,25919,31966,95957,300
Total operating expenses111,04590,878333,580254,777
Loss from operations(107,486)(85,593)(235,400)(218,630)
Interest and other income, net4,1871,0058,1143,310
Loss before income taxes(103,299)(84,588)(227,286)(215,320)
Income tax expense00(27)0
Net loss(103,299)(84,588)(227,313)(215,320)
Other comprehensive income (loss):    
Net unrealized gain (loss) on marketable securities, net of tax421(153)(9,354)(276)
Comprehensive loss$ (102,878)$ (84,741)$ (236,667)$ (215,596)
Net loss per share, basic (usd per share)$ (0.84)$ (0.69)$ (1.85)$ (1.77)
Net loss per share, diluted (usd per share)$ (0.84)$ (0.69)$ (1.85)$ (1.77)
Weighted average number of shares outstanding, basic (in shares)123,473,390121,742,067123,054,889121,309,197
Weighted average number of shares outstanding, diluted (in shares)123,473,390121,742,067123,054,889121,309,197
[1]Includes related-party collaboration revenue from a customer of $0.2 million and $2.9 million for the three and nine months ended September 30, 2022, respectively, and $0.9 million and $2.5 million for the three and nine months ended September 30, 2021, respectively.
[2]Includes expense for cost sharing payments due to a related party of $1.4 million and $3.8 million for the three and nine months ended September 30, 2022, respectively, and an offset to expense from related-party cost sharing reimbursements of $1.2 million and $5.3 million for the three and nine months ended September 30, 2021, respectively.

DNLI Balance Sheet

2022-09-30
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Sep. 30, 2022
Dec. 31, 2021
Current assets:  
Cash and cash equivalents$ 118,615$ 293,477
Short-term marketable securities987,440571,930
Cost sharing reimbursements due from related party01,226
Prepaid expenses and other current assets32,47130,601
Total current assets1,138,526897,234
Long-term marketable securities0425,449
Property and equipment, net41,69238,865
Operating lease right-of-use assets31,27130,743
Other non-current assets16,11711,871
Total assets1,227,6061,404,162
Current liabilities:  
Accounts payable7,5394,779
Cost sharing payments due to related party1,4430
Accrued compensation13,25319,013
Accrued clinical and other research & development costs21,70115,887
Accrued manufacturing costs16,7329,955
Other accrued costs and current liabilities2,3952,857
Operating lease liabilities, current7,0685,453
Related-party contract liability, current290,516292,386
Contract liabilities, current2327,915
Total current liabilities360,670378,245
Related-party contract liability, less current portion2761,295
Contract liabilities, less current portion03,398
Operating lease liabilities, less current portion54,97858,554
Other non-current liabilities379379
Total liabilities416,303441,871
Commitments and contingencies (Note 6)
Stockholders' equity:  
Convertible preferred stock, $0.01 par value; 40,000,000 shares authorized as of September 30, 2022 and December 31, 2021; 0 shares issued and outstanding as of September 30, 2022 and December 31, 202100
Common stock, $0.01 par value; 400,000,000 shares authorized as of September 30, 2022 and December 31, 2021; 123,796,438 shares and 122,283,305 shares issued and outstanding as of September 30, 2022 and December 31, 2021, respectively1,5641,548
Additional paid-in capital1,693,9011,608,238
Accumulated other comprehensive loss(11,853)(2,499)
Accumulated deficit(872,309)(644,996)
Total stockholders' equity811,303962,291
Total liabilities and stockholders’ equity$ 1,227,606$ 1,404,162